Oncopeptides AB: Interim Report Q1 2020
Oncopeptides AB: Interim Report Q1 2020 |
[26-May-2020] |
STOCKHOLM, May 26, 2020 /PRNewswire/ -- Financial overview January 1 - March 31, 2020
Significant events during the period January 1 - March 31, 2020
Significant events after the reporting period
Financial overview of the group
1) Earlier periods have been adjusted to reflect correction of errors, see note 6. Conference call for investors, analysts and the media The Interim Report Q1 2020 and an operational update will be presented by CEO Jakob Lindberg and members of Oncopeptides management team, Tuesday May 26, 2020 at 10:00 (CET). The conference call will also be streamed via a link on the website: www.oncopeptides.com. Phone numbers for participants from: Sweden: +46-8-505-583-57 Europe: +44-3333-009-271 USA: +1-833-526-83-98 Financial calendar Annual General Meeting May 26, 2020 Interim Report Q2, 2020: August 26, 2020 Interim Report Q3, 2020: November 19, 2020 For further information Rein Piir This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on May 26, 2020. About Oncopeptides Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen (melphalan flufenamide) is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides' headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information please visit www.oncopeptides.com. This information was brought to you by Cision http://news.cision.com https://news.cision.com/oncopeptides-ab/r/interim-report-q1-2020,c3119486 The following files are available for download:
View original content:http://www.prnewswire.com/news-releases/oncopeptides-ab-interim-report-q1-2020-301064965.html SOURCE Oncopeptides AB | ||||||||||||||||||||||||||||||||||||||||||
Company Codes: Stockholm:ONCO, ISIN:SE0009414576, RICS:ONCO.ST, Berlin:OND, LSE:0RN4, Bloomberg:ONCO@SS, Frankfurt:OND, RICS:ONCO.ST |
© 2020 PR Newswire. All Rights Reserved.